Compare Bristol-Myers Squibb Co (BMY) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NIO Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.82 (market cap $129.94B), while NIO Inc. trades at $4.56 (market cap $11.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 11.2× NIO Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| BMY | NIO | |
|---|---|---|
Market Cap | $129.94B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $7.89 |
52-Week Low | $42.60 | $4.44 |
Enterprise Value | $163.92B | $10.82B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
NIO's stock trades at $4.575, down 5.08% amid bearish technical signals and negative cash flows. Revenue grew to $87.49 billion in 2025, but net losses persist at -$15.57 billion. Recent news highlights delivery growth and competitive pressures in China's EV market, with shares near support levels after a steep decline from 2026 highs.
The outlook remains challenged by profitability concerns and high debt, though analyst consensus leans bullish with 54% buy ratings. Key risks include intense competition and reliance on financing, while potential upside hinges on margin improvement and sustained delivery growth in a volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
